Aragen has announced CHOMax, a new cell line development and early manufacturing platform. The platform supports an integrated pathway from DNA to investigational new drug (IND)-enabling clinical supply. For suitable, standard immunoglobulin G (IgG) monoclonal antibodies, Aragen says that timeline can be reduced to approximately 10 months.

Refined across more than 200 Chinese hamster ovary (CHO) programs, CHOMax integrates numerous factors. These include cell line and process development, analytics, and good manufacturing practice (GMP) manufacturing. This integration takes into account quality processes that satisfy account global regulatory expectations.

Aragen Leaders React

“Our proprietary CHOMax platform takes uncertainty out of early biologics development,” said Ashu Tandon, Aragen Chief Commercial Officer. “By combining a proven CHO host lineage, time-tested CMC [chemistry, manufacturing, and controls] workflows, and royalty‑free financial model, Aragen moves antibody programs from DNA to IND‑enabling clinical supply in a matter of months, generating sustainable value for our customers.”

“CHOMax gives sponsors a clearly structured pathway to IND-enabling clinical supply,” added Subodh Deshmukh, Aragen Biologics CEO.

More Aragen News

In October 2025, Aragen named Neeraj Garg CEO of its Discovery Solutions business. Garg’s responsibilities include crafting strategy, driving profits, expanding client base, improving efficiencies, and incubating new capabilities to accelerate research.

“Aragen has built a tremendous pedigree as a global CRDMO leader and, during the last few years, it has formed strategic partnerships with increasing number of global pharma; so I am joining at a pivotal stage for the company,” Garg said at the time. “I look forward to working with our talented teams to deliver exceptional value to our customers, accelerate scientific breakthroughs, and drive translational research that will help discover the medicines of tomorrow.”